期刊文献+

替吉奥在我院抗肿瘤治疗中的应用分析 被引量:1

在线阅读 下载PDF
导出
摘要 目的了解江苏盛泽医院(以下简称“我院”)近年来替吉奥在抗肿瘤治疗中的临床应用情况,探讨替吉奥的使用特点和趋势,以促进该药的临床合理使用。方法统计替吉奥的金额、用药频度等,并对统计结果进行分析。回顾性收集2014~2018年我院接受替吉奥治疗的203例肿瘤患者的病历资料,对患者的肿瘤类型、治疗方案、治疗周期进行统计和分析。结果近五年来,替吉奥的用药频度与使用金额一致总体呈增长趋势,平均日费用越来越低;203例患者共涉及13类恶性肿瘤,以胃癌、结直肠癌为主;治疗方案中以替吉奥单用为主,其次为联合奥沙利铂;有12例患者因不良反应而未完成一个周期的替吉奥化疗,有76例次进行替吉奥长期维持治疗。结论替吉奥作为一种氟尿嘧啶衍生物口服抗肿瘤药已广泛应用到胃癌、结直肠癌、胰腺癌、肺癌等治疗中,但其联合用药方案,维持治疗疗效、安全性有待进一步研究。
出处 《海峡药学》 2020年第6期101-104,共4页 Strait Pharmaceutical Journal
基金 吴江区卫生局“科教兴卫”研究项目(WWK201814)。
  • 相关文献

参考文献5

二级参考文献47

  • 1Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin,2015,65(2) :87 - 108.
  • 2Cervantes A, Roda D, Tarazona N, et al. Current questions for the treatment of advaneed gastric cancer [ J ]. Cancer Treat Rev, 2013, 39(1) :60 -7.
  • 3Koizumi W, Takiuehi H, Yamada Y, et al. Phase Ⅱ study of oxali- platin plus S-1 as first-line treatment for advanced gastrie cancer (G-SOXstudy)[J]. AnnOncol, 2010, 21(5) :1001-5.
  • 4Yamada Y,Higuchi K, Nishikawa K, et al. Phase Ⅲ study compa- ring oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy- naive patients with advanced gastric cancer [ J ]. Ann Oncol, 2015, 26(1) :141 -8.
  • 5Croteau D L, Peng Y, Van Houten B. DNA repair gets physical: mapping an XPA-binding site on ERCC1 [J ]. DNA Repair (Amst) ,2008,7(5) :819 -26.
  • 6Chen S, Zhang J, Wang R, et al. The platinum-based treatments for advanced nonsmalleell lung cancer, is low/negative ERCC1 ex- pression better than high/positive ERCC1 expression.'? A meta-a- nalysis [ J ]. Lung Cancer, 2010, 70 ( 1 ) :63 - 70.
  • 7Gerhard R, Carvalho A, Carneiro V, et al. Clinicopathological significance of ERCC1 expression in breast cancer[ J]. Pathol Res Pract,2013, 209(6) :331 -6.
  • 8Kwon H C,Roh M S, Oh S Y, et al. Prognostic value of expres-sion of ERCC1, thymidylate synthase, and glutathione S-transfer- ase P1 for 5-fluorouracil/oxaliplatin chemotherapy inadvanced gas- tric cancer[J]. Ann 0ncol,2007,18(3) :504 -9.
  • 9Yamada Y, Boku N, Nishina T, et al. Impact of excision repair cross-complementing gene 1 ( ERCC1 ) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912[J]. Ann 0ncol,2013,24(10) : 25605.
  • 10Belani C P, Brodowicz T, Ciuleanu T E, et al. Quality of life in patients with advanced non-small-cell lung cancer given mainte- nance treatment with pemetrexed versus placebo (H3E-MC- JMEN) : results from a randomized, double-blind, phase 3 study [J]. Lancet Oncol, 2012,13(3):292-9.

共引文献47

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部